PDGFRB and hereditary clear cell renal cell carcinoma: Differently, sunitinib is a small molecule with selectivity for PDGFR, VEGFR1, VEGFR2, KIT, and FLT3 (Mendel et al., 2003; O’Farrell et al., 2003), which is currently approved for treating renal cell carcinoma, gastrointestinal stromal tumor, and AML (Wu et al., 2018); however, until now, it has been considered only for FLT3 mutated AML patients in combination with chemotherapy (Fiedler et al., 2015).